SCHEMBL1735539

SCHEMBL1735539

CCN(CC)c1nc(C(N)=O)cc(-c2ccc(C(=O)OC)cc2)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.70
ALDH1A1 P00352 6/20 0.55
HPGD P15428 5/20 0.55
NPSR1 Q6W5P4 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
GLA P06280 2/20 0.55
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 4/20 0.44
LMNA P02545 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734575 0.88 KDM4E (0.70) KDM4EALDH1A1HPGDNPSR1SMN1; SMN2
SCHEMBL1734177 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDNPSR1SMN1; SMN2
SCHEMBL1734448 0.85 KDM4E (0.76) KDM4EALDH1A1HPGDNPSR1SMN1; SMN2
SCHEMBL1735810 0.84 KDM4E (0.78) KDM4EALDH1A1HPGDNPSR1GLA
SCHEMBL1733735 0.83 KDM4E (0.76) KDM4EALDH1A1HPGDSMN1; SMN2MEN1
SCHEMBL1734337 0.83 KDM4E (0.76) KDM4EALDH1A1HPGDFPR2SCN9A
SCHEMBL1733607 0.82 KDM4E (1.00) KDM4EALDH1A1HPGDNPSR1SMN1; SMN2
SCHEMBL1733602 0.82 KDM4E (0.67) KDM4EALDH1A1HPGDSMN1; SMN2MEN1
SCHEMBL1734269 0.82 KDM4E (0.71) KDM4EALDH1A1HPGDNPSR1SMN1; SMN2
SCHEMBL1734324 0.81 KDM4E (0.67) KDM4EALDH1A1HPGDMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
CN-101223146-A Modulators of ATP-binding cassette transporters VERTEX PHARMA (US) 2008-07-16 CN claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885ALDH1A1 2670/4885HPGD 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.